Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

40.73
+0.20000.49%
Pre-market: 40.730.00000.00%06:56 EDT
Volume:1.48M
Turnover:60.68M
Market Cap:2.91B
PE:-8.73
High:42.25
Open:41.55
Low:39.50
Close:40.53
52wk High:56.05
52wk Low:18.53
Shares:71.36M
Float Shares:50.20M
Volume Ratio:0.98
T/O Rate:2.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6644
EPS(LYR):-4.6644
ROE:-50.71%
ROA:-28.36%
PB:4.81
PE(LYR):-8.73

Loading ...

Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%

Reuters
·
Feb 26

BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55

Reuters
·
Feb 26

Vera Therapeutics FY Operating Expenses USD 315.473 Million

THOMSON REUTERS
·
Feb 26

Vera Therapeutics FY EPS USD -4.66 VS. Ibes Estimate USD -4.55

THOMSON REUTERS
·
Feb 26

Vera Therapeutics Inc - Atacicept Commercial Launch Expected Mid-2026

THOMSON REUTERS
·
Feb 26

Press Release: Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Dow Jones
·
Feb 26

Vera Therapeutics to Present at TD Cowen Annual Health Care Conference

Reuters
·
Feb 24

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Feb 24

Evercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)

TIPRANKS
·
Feb 17

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton

Reuters
·
Jan 31

Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Dow Jones
·
Jan 28

Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress

Simply Wall St.
·
Jan 27

Vera Therapeutics Grants Stock Options and RSUs to New Employees Under 2024 Inducement Plan

Reuters
·
Jan 10

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods

Reuters
·
Jan 07

BUZZ-Vera soars as FDA accepts priority review for kidney disease drug

Reuters
·
Jan 07

Vera Therapeutics Shares up 14.4% Premarket After Co Receives U.S. FDA Priority Review for Kidney Disease Drug

THOMSON REUTERS
·
Jan 07

BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application

Reuters
·
Jan 07

FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy

Reuters
·
Jan 07